Analyzing Biorestorative Therapies (NASDAQ:BRTX) & Protagonist Therapeutics (NASDAQ:PTGX)

Protagonist Therapeutics (NASDAQ:PTGX) and Biorestorative Therapies (NASDAQ:BRTX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, risk, earnings, valuation, institutional ownership and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Protagonist Therapeutics and Biorestorative Therapies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0	2	15	1	2.94
Biorestorative Therapies	1	0	0	0	1.00

Protagonist Therapeutics currently has a consensus price target of $137.86, indicating a potential downside of 11.12%. Given Protagonist Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Protagonist Therapeutics is more favorable than Biorestorative Therapies.

Profitability

This table compares Protagonist Therapeutics and Biorestorative Therapies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

Insider and Institutional Ownership

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Protagonist Therapeutics has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500. Comparatively, Biorestorative Therapies has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.

Earnings and Valuation

This table compares Protagonist Therapeutics and Biorestorative Therapies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$281.99 million	35.59	-$130.15 million	$1.03	150.58
Biorestorative Therapies	$357,870.00	16.08	-$14.24 million	($1.07)	-0.21

Biorestorative Therapies has lower revenue, but higher earnings than Protagonist Therapeutics. Biorestorative Therapies is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Protagonist Therapeutics beats Biorestorative Therapies on 13 of the 15 factors compared between the two stocks.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

About Biorestorative Therapies

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.